Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
Date of Report: October 15, 2018
Company: Emergent BioSolutions Inc.
Event: Completion of the acquisition of Adapt Pharma Limited ("Adapt") and refinancing of credit facilities.
Emergent completed the purchase of 100% of the equity interests in Adapt, a company that owns and commercializes NARCAN® (naloxone hydrochloride) Nasal Spray and maintains a development pipeline for opioid overdose treatments.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Approximately $575 million in cash and $60 million in stock at closing (exclusive of adjustments and holdbacks).
- Stock Issuance: 733,309 shares of Common Stock issued at a volume-weighted average price of $65.28 per share (aggregate value ~$47.9 million inclusive of adjustments).
- Contingent Consideration: Up to $100 million in cash payable based on sales milestones through 2022.
- Financing Structure:
- Revolving Credit Facility: Increased from $200 million to $600 million. Total borrowings at closing: $318 million.
- Term Loan Facility: New facility of $450 million, fully drawn at closing.
- Total New Debt Incurred: $668 million ($318 million revolver + $450 million term loan).
- Debt Maturity: Both facilities mature on October 13, 2023.
- Interest Rates: Eurocurrency rate plus 1.25% to 2.00% margin, or Base Rate plus 0.25% to 1.00% margin, depending on leverage ratio.
Material Changes Versus Prior Period
The filing details a significant expansion of Emergent's debt capacity and leverage profile to fund the Adapt acquisition:
- Debt Capacity: Revolving credit facility tripled from $200 million to $600 million.
- Outstanding Debt: Prior to the transaction, the revolver balance was approximately $100 million. Post-transaction, total borrowings under the Senior Secured Credit Facility reached $768 million ($318 million revolver + $450 million term loan).
- Covenant Adjustments: The maximum consolidated net leverage ratio covenant was amended to 4.00 to 1.00 through September 29, 2019, stepping down to 3.75 to 1.00 in 2020 and 3.50 to 1.00 thereafter (with a temporary step-up to 4.00 to 1.00 permitted for material acquisitions).
- Equity: Issuance of 733,309 new shares of common stock.
Guidance, Outlook, Risks, and Contingencies
Management Commentary: The acquisition expands Emergent's portfolio to include NARCAN® Nasal Spray and a pipeline of opioid overdose treatments. Proceeds from the new debt were used to finance the acquisition and related fees, with the remainder for general corporate purposes.
Risks and Covenants:
- Financial Covenants: Emergent must maintain a minimum consolidated debt service coverage ratio of 2.50 to 1.00.
- Events of Default: Include payment defaults, bankruptcy, change of control, mandatory product recalls (if sales exceed a specified amount), and if greater than 50% of federal government accounts receivable are past due for more than 90 days.
- Restrictions: Negative covenants limit the ability to incur additional indebtedness, dispose of assets, or make investments without meeting specific financial tests.
- Lock-up: Sellers agreed to a two-year lock-up on the shares of Common Stock received in the transaction.
Unusual Items: The filing notes that pro forma financial information and financial statements of the acquired business (Adapt) are not included in this report but will be filed within 71 calendar days.
Key Facts for Investor Verification
- Verify the pro forma financial impact of the $668 million in new debt on Emergent's leverage ratios once the 71-day filing is submitted.
- Monitor the achievement of sales milestones required to trigger the up to $100 million in contingent cash payments through 2022.
- Review the specific terms of the "mandatory product recalls" event of default, as this could trigger acceleration of debt if NARCAN® or other products face significant regulatory issues.
- Confirm the utilization of the $600 million revolving credit facility, as $318 million was drawn immediately, leaving $282 million available.
- Assess the dilution impact of the 733,309 shares issued to Adapt shareholders.